Opinion|Videos|June 26, 2024
Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
Looking to the future of Alzheimer disease treatment, the panel discusses key takeaways on the evolving therapeutic landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Looking to the future of Alzheimer disease treatment, what are your key takeaways on the evolving therapeutic landscape?
Advertisement
Related to this article
Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.
Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
The EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Pooled data on 2698 patients tie rituximab maintenance after bendamustine-rituximab to better PFS and OS in mantle cell lymphoma.
Among 788 patch-tested patients with hand eczema in Shanghai, 82% reacted to at least 1 allergen.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
3
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
4
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
5